Gapping down
In reaction to disappointing earnings/guidance: GNC -24.2%, OCN -19.7%, SGI -15.7%, INFN -13.9%, OSIS -10.9%, (also authorizes additional 1 mln share buyback), DPZ -10.6%, AME -10.2%, HAR -10%, MSTR -9.5%, SYMC -9.4%, OTEX -8.6%, (also announced plans to acquire ANXeBusiness for ~$100 mln, expects earnings accretion immediately; increased dividend),PRXL -8.6%, ABT -8.3%, CAVM -8.2%, SJW -6.7%, (light volume), POT -6.6%, LOCK -6.1%, CRR -6%, BZH -5.5%, WLL-5.2%, FIX -5%, (also increases quarterly dividend to $0.07/share from $0.065/share ), LLNW -4.9%, TPX -4.6%, LYG -4.4%,RCII -4.2%, ALXN -3.8%, TS -3.7%, XLNX -3.4%, (also raises quarterly dividend 6.5% to $0.33/share ), ORLY -3.3%, MPC-3.3%, MPLX -3.2%, AR -3%, VRTX -2.7%, BKCC -2.7%, AEP -2.6%, FSLR -2.5%, (also Chief Financial Officer Mark R. Widmar has been appointed Chief Executive Officer), XL -2.4%, TER -2.3%, VAR -2.2%, TMO -2%, PF -1.7%, CELG -1.6%, BLL -1.5%,TYL -1.3%, BKFS -1.2%, CIT -1.2%, COP -1.1%
M&A news: ABT -7.7% (to acquire St. Jude Medical for $46.75 in cash and 0.8708 shares of Abbott common stock), ABBV-3.7% (to acquire Stemcentrx for ~$5.8 bln in cash & stock, updates FY16 guidance)
Other news: SGYP -1.4% (CFO Gary Sender resigns for personal reasons effective April 30, Bernard Denoyer to assume role as Principal Financial Officer as co conducts search for replacement), ARMH -1.3% (after INFN earnings), RXDX -1.1% ( commences ~$50 mln common stock offering), RXDX -1.1% (says that in the ongoing Phase 1 clinical trial of oral taladegib in patients with solid tumors, a complete response was observed in a patient with medulloblastoma), TROV -1.1% (Board member Antonius Schuh resigns, says his resignation is a result of the Board's failure to run a thorough external search process, the Board hastily appointing Bill Welch as CEO this past weekend)
Analyst comments: WLL -3.6% (downgraded to Sector Perform at RBC Capital Mkts), X -2.7% (downgraded to Underperform from Neutral at Macquarie), MANH -2.5% (downgraded to Market Perform at William Blair), CG -1.1% (downgraded to Mkt Perform from Outperform at Keefe Bruyette)
In reaction to disappointing earnings/guidance: GNC -24.2%, OCN -19.7%, SGI -15.7%, INFN -13.9%, OSIS -10.9%, (also authorizes additional 1 mln share buyback), DPZ -10.6%, AME -10.2%, HAR -10%, MSTR -9.5%, SYMC -9.4%, OTEX -8.6%, (also announced plans to acquire ANXeBusiness for ~$100 mln, expects earnings accretion immediately; increased dividend),PRXL -8.6%, ABT -8.3%, CAVM -8.2%, SJW -6.7%, (light volume), POT -6.6%, LOCK -6.1%, CRR -6%, BZH -5.5%, WLL-5.2%, FIX -5%, (also increases quarterly dividend to $0.07/share from $0.065/share ), LLNW -4.9%, TPX -4.6%, LYG -4.4%,RCII -4.2%, ALXN -3.8%, TS -3.7%, XLNX -3.4%, (also raises quarterly dividend 6.5% to $0.33/share ), ORLY -3.3%, MPC-3.3%, MPLX -3.2%, AR -3%, VRTX -2.7%, BKCC -2.7%, AEP -2.6%, FSLR -2.5%, (also Chief Financial Officer Mark R. Widmar has been appointed Chief Executive Officer), XL -2.4%, TER -2.3%, VAR -2.2%, TMO -2%, PF -1.7%, CELG -1.6%, BLL -1.5%,TYL -1.3%, BKFS -1.2%, CIT -1.2%, COP -1.1%
M&A news: ABT -7.7% (to acquire St. Jude Medical for $46.75 in cash and 0.8708 shares of Abbott common stock), ABBV-3.7% (to acquire Stemcentrx for ~$5.8 bln in cash & stock, updates FY16 guidance)
Other news: SGYP -1.4% (CFO Gary Sender resigns for personal reasons effective April 30, Bernard Denoyer to assume role as Principal Financial Officer as co conducts search for replacement), ARMH -1.3% (after INFN earnings), RXDX -1.1% ( commences ~$50 mln common stock offering), RXDX -1.1% (says that in the ongoing Phase 1 clinical trial of oral taladegib in patients with solid tumors, a complete response was observed in a patient with medulloblastoma), TROV -1.1% (Board member Antonius Schuh resigns, says his resignation is a result of the Board's failure to run a thorough external search process, the Board hastily appointing Bill Welch as CEO this past weekend)
Analyst comments: WLL -3.6% (downgraded to Sector Perform at RBC Capital Mkts), X -2.7% (downgraded to Underperform from Neutral at Macquarie), MANH -2.5% (downgraded to Market Perform at William Blair), CG -1.1% (downgraded to Mkt Perform from Outperform at Keefe Bruyette)